EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis

Joseph Azuri iD, Ariel Hammerman iD, Enis Aboalhasan iD, Ben Sluckis, Ronen Arbel

Obesity · 2023

DOI: 10.1002/oby.23752 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Obesity, 2023. Verfasst von Joseph Azuri und 4 weiteren Autor:innen. Beteiligte Einrichtung: Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Liraglutide, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Higher doses of the glucagon‐like peptide‐1 agonists liraglutide and, more recently, semaglutide have demonstrated a significant reduction in body weight. However, their comparative value for money for this indication is unclear.

Methods

The cost needed to treat to achieve a 1% reduction in body weight using semaglutide or liraglutide was calculated. The body weight reductions were extracted from the published STEP 1 trial and the SCALE trial results, respectively. A scenario analysis was performed to mitigate the primary differences between the two studies' populations. Drug costs were based on US GoodRx prices as of October 2022.

Results

Liraglutide in STEP 1 resulted in a weight loss of 5.4% (95% CI: 5%‐5.8%). Semaglutide in SCALE resulted in a weight loss of 12.4% (95% CI: 11.5%‐13.4%). The total cost of therapy with liraglutide during the trial was estimated at $17,585 compared with $22,878 with semaglutide. Accordingly, the cost needed to treat per 1% of body weight reduction with liraglutide is estimated at $3256 (95% CI: $3032‐$3517) compared with $1845 (95% CI: $1707‐$1989) with semaglutide.

Conclusions

Semaglutide provides significantly better value for money than liraglutide for weight reduction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiraglutideDiabetes Mellitus, Type 2HumansHypoglycemic AgentsGlycated HemoglobinWeight LossBody WeightSemaglutide

Substanzen

LiraglutideHypoglycemic AgentsGlycated HemoglobinSemaglutide

Autor:innen und Institutionen

  • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Maccabi Healthcare Services, Tel Aviv, Israel.
  • Clalit Health Services, Tel Aviv, Israel.
  • Maximizing Health Outcomes Research Lab, Sapir College, Israel.
  • Meuhedet Health Services, Jerusalem, Israel.

ORCID-Profile: Joseph Azuri, Ariel Hammerman, Enis Aboalhasan

Zitieren

APA

Azuri, J., Hammerman, A., Aboalhasan, E., Sluckis, B., & Arbel, R. (2023). Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis. Obesity. https://doi.org/10.1002/oby.23752

Vancouver

Azuri J, Hammerman A, Aboalhasan E, Sluckis B, Arbel R. Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis. Obesity. 2023. doi:10.1002/oby.23752

BibTeX
@article{Azuri2023,
  author = {Azuri, Joseph and Hammerman, Ariel and Aboalhasan, Enis and Sluckis, Ben and Arbel, Ronen},
  title = {Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis},
  journal = {Obesity},
  year = {2023},
  doi = {10.1002/oby.23752}
}
Kostenlos starten →